Market
AstraZeneca/Daiichi Sankyo reapply for EU approval of Dato-DXd by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
European Medicines Agency announcements or AstraZeneca/Daiichi Sankyo press releases
Story
AstraZeneca and Daiichi Sankyo Withdraw EU Application for Lung Cancer Drug Datopotamab Deruxtecan Due to Non-Significant Survival Improvement
Dec 24, 2024, 11:37 AM
AstraZeneca, in collaboration with Daiichi Sankyo, has voluntarily withdrawn its marketing authorization application for the lung cancer drug datopotamab deruxtecan ($Dato-DXd) from the European Union's medicines regulator. The decision follows feedback from the European Medicines Agency after trial results from the phase advanced study TROPION-Lung01 showed that the drug did not significantly improve patient survival rates. The drug, also known as Dato-DXd, had previously received the designation of innovative therapy from the U.S. Food and Drug Administration earlier this month for its results in treating a specific type of lung cancer. Dato-DXd belongs to a promising group of treatments known as antibody-drug conjugates.
View original story
Similar markets
Yes • 50%
No • 50%
10 to 20 countries • 25%
More than 30 countries • 25%
Less than 10 countries • 25%
21 to 30 countries • 25%
Roche • 25%
None of the above • 25%
Pfizer • 25%
Novartis • 25%
No • 50%
Yes • 50%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
3 or more • 25%
0 • 25%
1 • 25%
2 • 25%
Yes • 50%
No • 50%
